177Lu-[DOTA0, Tyr3] octreotate therapy in iodine refractory thyroid cancer: Comparison of dosimetry with therapy of thyroid cancer and neuroendocrine tumors

被引：0
|
作者：
Yeyin, Nami [1 ]
Toklu, Turkay [2 ]
Demirci, Emre [1 ]
Kabasakal, Levent [1 ]
Aygun, Aslan [1 ]
Ocak, Meltem [3 ]
Selcuk, Nalan [2 ]
Kanmaz, Bedii [1 ]
机构：
[1] Istanbul Univ, Cerrahpasa Med Fac, Dept Nucl Med, Istanbul, Turkey
[2] Yeditepe Univ, Med Sch, Dept Nucl Med, Istanbul, Turkey
[3] Istanbul Univ, Pharm Fac, Dept Phannaceut Technol, Istanbul, Turkey
来源：
JOURNAL OF NUCLEAR MEDICINE | 2012年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
2104
引用
收藏
页数：1
相关论文
共 50 条
  • [1] 177Lu-[DOTA0,Tyr3] octreotate therapy in iodine refractory thyroid cancer: Comparison of dosimetry with therapy of thyroid cancer and neuroendocrine tumors
    Yeyin, N.
    Demirci, E.
    Toklu, T.
    Kabasakal, L.
    Aygun, A.
    Ocak, M.
    Selcuk, N.
    Kanmaz, B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S306 - S306
  • [2] 177Lu-[DOTA0,Tyr3] Octreotate Therapy in Patients With Disseminated Neuroendocrine Tumors: Analysis of Dosimetry With Impact on Future Therapeutic Strategy
    Garkavij, Michael
    Nickel, Mattias
    Sjogreen-Gleisner, Katarina
    Ljungberg, Michael
    Ohlsson, Tomas
    Wingardh, Karin
    Strand, Sven-Erik
    Tennvall, Jan
    CANCER, 2010, 116 (04) : 1084 - 1092
  • [3] Comparison of [177Lu-DOTA0, Tyr3] octreotate and [177Lu- DOTA0, Tyr3] octreotide:: which peptide is preferable for PRRT?
    Esser, J. P.
    Krenning, E. P.
    Teunissen, J. J. M.
    Kooij, P. P. M.
    van Gameren, A. L. H.
    Bakker, W. H.
    Kwekkeboom, D. J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 (11) : 1346 - 1351
  • [4] Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [177Lu-[DOTA0, Tyr3]-octreotate
    Santoro, Lore
    Mora-Ramirez, Erick
    Trauchessec, Dorian
    Chouaf, Soufiane
    Eustache, Pierre
    Pouget, Jean-Pierre
    Kotzki, Pierre-Olivier
    Bardies, Manuel
    Deshayes, Emmanuel
    EJNMMI RESEARCH, 2018, 8
  • [5] Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [177Lu-[DOTA0, Tyr3]-octreotate
    Lore Santoro
    Erick Mora-Ramirez
    Dorian Trauchessec
    Soufiane Chouaf
    Pierre Eustache
    Jean-Pierre Pouget
    Pierre-Olivier Kotzki
    Manuel Bardiès
    Emmanuel Deshayes
    EJNMMI Research, 8
  • [6] Practical aspects of peptide receptor radionuclide therapy with [177Lu][DOTA0, Tyr3]octreotate
    Bakker, W. H.
    Breeman, W. A. P.
    Kwekkeboom, D. J.
    De Jong, L. C.
    Krenning, E. P.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 50 (04): : 265 - 271
  • [7] [177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors
    Halperin, Daniel M.
    Dasari, Arvind
    Yao, James C.
    FUTURE ONCOLOGY, 2016, 12 (03) : 313 - 321
  • [8] Comparison of 111IN-[DTPA0]Octreotide and 177Lu-[DOTA0,Tyr3]Octreotate in Patients treated for Gastroenteropancreatic Tumours
    Limouris, G. S.
    Karfis, I.
    Paphiti, M. I.
    McCready, V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S332 - S333
  • [9] Comparison and Evaluation of n.c.a. 177Lu-[DOTA0, Tyr3] TATE vs n.c.a. 177Lu-[DOTA0, Tyr3] TOC in (GEP-NENs) Treated Patients
    Limouris, G. S.
    Paphiti, M.
    Souvatzoglou, M.
    Moulopoulou, L. E.
    McCready, R. V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S420 - S421
  • [10] Effects of therapy with [177Lu-DOTA0,Tyr3]octreotate on endocrine function
    Teunissen, Jaap J. M.
    Krenning, Eric P.
    de Jong, Frank H.
    de Rijke, Yolanda B.
    Feelders, Richard A.
    van Aken, Maarten O.
    de Herder, Wouter W.
    Kwekkeboom, Dik J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 (11) : 1758 - 1766
12345